Jerel Davis, PhD

Managing Director, Versant Ventures

Jerel is a Managing Director based at Versant Ventures. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups.

+ Show More

Todd Foley

Managing Director, MPM Capital

Todd is a Managing Director at MPM Capital. He focuses on biotech investments, and in addition to serving on Repare’s board, he serves on a number of MPM portfolio company boards, including Switch Bio, Chiasma (CHMA), ClinicalInk, Iconic, Rhythm, Semma and Tetherex.

+ Show More

Briggs W. Morrison, MD

CEO, Syndax Pharmaceuticals

Briggs is the CEO of Syndax Pharmaceuticals (NASDAQ:SNDX), a biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Dr. Morrison also currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm.

+ Show More

Carol Schafer

Financial Professional

Carol is a seasoned financial professional with more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development. She most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities.

+ Show More

Lloyd M. Segal

President & CEO, Repare Therapeutics

In addition to his role as Repare’s President & CEO, Lloyd is an Entrepreneur-in-residence at Versant Ventures. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor. Lloyd held CEO roles at Caprion Pharmaceticals, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.

+ Show More